Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 22, 2021 3:57pm
155 Views
Post# 34154322

RE:Partnership coming or not? No one believes cancer news…

RE:Partnership coming or not? No one believes cancer news…I thought about the selling pressure too, but came to the conclusion that given the highly conservative nature of management, the fact most are remote still, and the fact we analyze every darn clue there is released or not, that I just don't think there is any group of investors that knows a whole lot more than we do about the cancer opportunity.  So I discount that someone has ferreted out an aspect of the program to justify the selling.

Now that doesn't at all preclude someone from just determining they don't want to deal with the timeline, or the risk, or they are looking more generally at the cancer  space and seeing numerous new technologies looking to tackle the issue; hence, a highly competitive space.  Those can easily be reasons to move out, but I don't think it's that there has been a negative signal on the progress of the Phase 1a trial.  

On NASH, they're now about 3 months in to a likely 6 to 12 month process.  I think we'll have to wait still for any partnership discussions for NASH and, if and when they come about, don't expect a lot of upfront money changing hands. 



Dcutter101 wrote: So let's Get NASH going!!!


<< Previous
Bullboard Posts
Next >>